Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse

Author:

Garg Manoj1ORCID,Nagata Yasunobu2,Kanojia Deepika1,Mayakonda Anand1,Yoshida Kenichi2,Haridas Keloth Sreya1,Zang Zhi Jiang1,Okuno Yusuke3,Shiraishi Yuichi4,Chiba Kenichi4,Tanaka Hiroko5,Miyano Satoru5,Ding Ling-Wen1,Alpermann Tamara6,Sun Qiao-Yang1,Lin De-Chen1,Chien Wenwen1,Madan Vikas1,Liu Li-Zhen1,Tan Kar-Tong1,Sampath Abhishek1,Venkatesan Subhashree1,Inokuchi Koiti7,Wakita Satoshi7,Yamaguchi Hiroki7,Chng Wee Joo1,Kham Shirley-Kow Yin8,Yeoh Allen Eng-Juh8,Sanada Masashi29,Schiller Joanna10,Kreuzer Karl-Anton10,Kornblau Steven M.1112,Kantarjian Hagop M.1112,Haferlach Torsten6,Lill Michael13,Kuo Ming-Chung14,Shih Lee-Yung14,Blau Igor-Wolfgang15,Blau Olga15,Yang Henry1,Ogawa Seishi2,Koeffler H. Phillip11316

Affiliation:

1. Cancer Science Institute of Singapore, National University of Singapore, Singapore;

2. Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;

3. Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan;

4. Laboratory of DNA Information Analysis, and

5. Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan;

6. Munich Leukemia Laboratory, Munich, Germany;

7. Department of Hematology, Nippon Medical School, Tokyo, Japan;

8. Department of Paediatrics, National University Health System, Singapore;

9. Department of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan;

10. Department I of Internal Medicine, University of Cologne, Cologne, Germany;

11. Department of Leukemia, MD Anderson Cancer Center, Houston, TX;

12. Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;

13. Cedars-Sinai Medical Center, Division of Hematology/Oncology, University of California Los Angeles, School of Medicine, Los Angeles, CA;

14. Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan;

15. Department of Hematology, Oncology and Tumorimmunology, Charite University School of Medicine, Berlin, Germany; and

16. National University Cancer Institute, National University Hospital, Singapore

Abstract

Key Points MLL3 acts as tumor suppressor in FLT3-ITD AML. The existence of DNMT3A mutations in remission samples implies that the DNMT3A mutant clone can survive induction chemotherapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 167 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3